Showing results (131-140 of 277) with videos related to
Sort By:
Pageof 28
Journal of the American Academy of Dermatology|July 8, 2010
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasisAlan Menter, Kenneth B Gordon, Craig L Leonardi, et al.Journal of Drugs in Dermatology : JDD|March 6, 2014
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regionsAlan Menter, Kim A Papp, Huaming Tan, et al.Dermatology and Therapy|May 19, 2020
Correction to: Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available EvidenceJashin J Wu, Joseph F Merola, Steven R Feldman, et al.Journal of the American Academy of Dermatology|January 19, 2016
The spectrum of nephrocutaneous diseases and associations: Genetic causes of nephrocutaneous diseaseJay Wofford, Andrew Z Fenves, J Mark Jackson, et al.Pediatric Dermatology|April 27, 2013
Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitisCaitriona Ryan, Richard E Shaw, Clay J Cockerell, et al.Dermatology and Therapy|November 18, 2019
Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe PsoriasisElsie Grace, Orin Goldblum, Lisa Renda, et al.Current Medical Research and Opinion|September 14, 2010
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trialArthur Kavanaugh, Alan Menter, Alan Mendelsohn, et al.Journal of the American Academy of Dermatology|May 22, 2004
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisChristopher S Carlin, Steven R Feldman, James G Krueger, et al.International Journal of Dermatology|March 26, 2003
Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacyNick J Lowe, John Gonzalez, Jerry Bagel, et al.Dermatologic Therapy|November 2, 2020
Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferencesAaminah Azhar, Marcus Zaayman, Annika Silfvast-Kaiser, et al.Pageof 28